Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Kristoffer Staal Rohrberg
- Target Recruit Count
- 3
- Registration Number
- NCT02125617
- Locations
- 🇩🇰
University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
Sequencing Abiraterone and Enzalutamide in mCRPC
- Conditions
- Interventions
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 202
- Registration Number
- NCT02125357
- Locations
- 🇨🇦
BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇦BC Cancer Agency - Southern Interior, Kelowna, British Columbia, Canada
🇨🇦Vancouver Prostate Centre, Vancouver, British Columbia, Canada
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT02123758
RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
- Conditions
- Interventions
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2022-06-27
- Target Recruit Count
- 112
- Registration Number
- NCT02090114
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- Arno Therapeutics
- Target Recruit Count
- 75
- Registration Number
- NCT02049190
- Locations
- 🇬🇧
Inst of Cancer Research & Royal Marsden NHS Foundation Trust, Sutton Surrey, United Kingdom
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
- Conditions
- Interventions
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 806
- Registration Number
- NCT02043678
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
- Conditions
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 68
- Registration Number
- NCT02034552
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT02025010
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center Commack, Commack, New York, United States
A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Cougar Biotechnology, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02001571
Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT01994590
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.